CGTX vs. SCYX, BCLI, INKT, BOLT, SBBP, SLDB, PSTX, ADAP, BDTX, and GNFT
Should you be buying Cognition Therapeutics stock or one of its competitors? The main competitors of Cognition Therapeutics include SCYNEXIS (SCYX), Brainstorm Cell Therapeutics (BCLI), MiNK Therapeutics (INKT), Bolt Biotherapeutics (BOLT), Strongbridge Biopharma (SBBP), Solid Biosciences (SLDB), Poseida Therapeutics (PSTX), Adaptimmune Therapeutics (ADAP), Black Diamond Therapeutics (BDTX), and Genfit (GNFT). These companies are all part of the "medical" sector.
Cognition Therapeutics (NASDAQ:CGTX) and SCYNEXIS (NASDAQ:SCYX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.
SCYNEXIS has a net margin of 72.18% compared to Cognition Therapeutics' net margin of 0.00%. SCYNEXIS's return on equity of 112.89% beat Cognition Therapeutics' return on equity.
SCYNEXIS received 496 more outperform votes than Cognition Therapeutics when rated by MarketBeat users. Likewise, 70.24% of users gave SCYNEXIS an outperform vote while only 56.25% of users gave Cognition Therapeutics an outperform vote.
In the previous week, Cognition Therapeutics had 8 more articles in the media than SCYNEXIS. MarketBeat recorded 11 mentions for Cognition Therapeutics and 3 mentions for SCYNEXIS. SCYNEXIS's average media sentiment score of 1.20 beat Cognition Therapeutics' score of 1.02 indicating that SCYNEXIS is being referred to more favorably in the news media.
Cognition Therapeutics presently has a consensus price target of $7.50, suggesting a potential upside of 284.62%. SCYNEXIS has a consensus price target of $15.00, suggesting a potential upside of 521.12%. Given SCYNEXIS's higher probable upside, analysts clearly believe SCYNEXIS is more favorable than Cognition Therapeutics.
SCYNEXIS has higher revenue and earnings than Cognition Therapeutics. Cognition Therapeutics is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks.
Cognition Therapeutics has a beta of 1.54, indicating that its stock price is 54% more volatile than the S&P 500. Comparatively, SCYNEXIS has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500.
43.4% of Cognition Therapeutics shares are owned by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are owned by institutional investors. 20.8% of Cognition Therapeutics shares are owned by insiders. Comparatively, 2.9% of SCYNEXIS shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
SCYNEXIS beats Cognition Therapeutics on 12 of the 16 factors compared between the two stocks.
Get Cognition Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CGTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cognition Therapeutics Competitors List
Related Companies and Tools
